A Phase 3 interventional study of Acetaminophen/Naproxen Sodium Fixed Combination and Placebo in Pain, sponsored by Johnson & Johnson Consumer Inc. (J&JCI). Completed at 4 sites in United States. Open to participants aged 16 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by Johnson & Johnson Consumer Inc. (J&JCI) (formerly part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 104 studies in Pain by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Pain · Johnson & Johnson.
Among the 104 studies in Pain by Johnson & Johnson, this one is the 48th largest by enrollment of the 88 interventional ones that give a count, is one of 3 that started in 2023, is one of 40 in phase 3, and was the 104th registered.
10,069 studies on the registry are indexed under Pain; 1,650 are open to participants now.
Browse Pain studies →None of the 104 studies in Pain by Johnson & Johnson is open now. The open studies under Pain, anywhere →
Of the 927 Pain studies recruiting now, 382 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 221 take healthy volunteers.
This study: 16 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
104 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 15 · Phase 3 41 · Phase 4 22
First in 1986; this study’s year is marked. 3 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 143 is above the median of 66 across 8,505 interventional studies indexed under Pain.
Median enrollment 183 across the 88 interventional studies, 636 across the 15 observational. Of the 99 that completed or were terminated, 32 (32%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Johnson & Johnson Consumer Inc. (J&JCI), one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Consumer Inc. (J&JCI) is the lead sponsor of 55 studies on the registry; none are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 104 studies in Pain by Johnson & Johnson, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate effectiveness of a fixed combination of acetaminophen/naproxen sodium compared with placebo for reduction of pain when administered as multiple doses over a 48-hour period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Postoperative Inclusion Criteria
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive oral doses of two Acetaminophen/Naproxen Sodium Fixed Combination tablets taken with water. Multiple doses will be administered over a 48-hour period.
Drug: Acetaminophen/Naproxen Sodium Fixed Combination
Participants will receive oral doses of two placebo tablets taken with water. Multiple doses will be administered over a 48-hour period.
Drug: Placebo
Fixed combination of Acetaminophen/Naproxen Sodium will be administered orally.
Placebo will be administered orally.
Time-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24)
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-24 hours. PID is ranging from 0 to 10 point and SPID0-24 ranging from 0 to 240. A higher value of SPID indicated greater pain relief.
Time frame: Baseline (0 hour) up to 24 hours post-dose
Time-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12)
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-12 hours. PID is ranging from 0 to 10 point and SPID0-12 ranging from 0 to120. A higher value of SPID indicated greater pain relief.
Time frame: Baseline (0 hour) up to 12 hours post-dose
Time-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48)
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-48 hours. PID is ranging from 0 to 10 point and SPID0-48 ranging from 0 to 480. A higher value of SPID indicated greater pain relief.
Time frame: Baseline (0 hour) up to 48 hours post-dose
Time to Confirmed Perceptible Pain Relief (TCPR)
TCPR is defined as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch, provided that the participant also stopped the second stopwatch indicating meaningful pain relief.
Time frame: Up to 12 hours
Time to Meaningful Pain Relief (TMPR)
TMPR is defined as the time (in minutes) to meaningful pain relief as indicated on the second stopwatch.
Time frame: Up to 12 hours
Time to First Use of Rescue Medication
Time to first use of rescue medication was measured as the elapsed time from when investigational product was given until the time rescue medication was first given.
Time frame: Up to 48 hours
Proportion of Participants Who Use Rescue Medication During the First 12 Hours
Proportion of participants who use rescue medication during the first 12 hours was reported.
Time frame: Up to 12 hours
| Milestone | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Started | 72 | 71 |
| Completed | 67 | 55 |
| Not completed | 5 | 16 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Lack of efficacy | 4 | 14 |
| Withdrew: Personal reasons | 1 | 0 |
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-24 hours. PID is ranging from 0 to 10 point and SPID0-24 ranging from 0 to 240. A higher value of SPID indicated greater pain relief.
| units on a scale*hours | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time-weighted Sum of Pain Intensity Difference Score From 0 to 24 Hours After Dosing (SPID 0-24) | 48.44 ± 5.074 | 14.16 ± 5.125 |
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-12 hours. PID is ranging from 0 to 10 point and SPID0-12 ranging from 0 to120. A higher value of SPID indicated greater pain relief.
| units on a scale*hours | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time-weighted SPID Score From 0 to 12 Hours After Dosing (SPID 0-12) | 15.22 ± 2.450 | 2.61 ± 2.467 |
Time-weighted sum of the pain intensity difference (SPID) scores were calculated using a Pain Intensity-Numerical Rating Scale (PI-NRS) ranging from 0-10 (0 = no pain, 10 = very severe pain) collected at each scheduled timepoint within the specified timeframe. The Pain Intensity Difference (PID) at each time point was derived by subtracting the pain intensity at that time point from the baseline pain intensity. The SPID scores were derived by first multiplying each PID score by the time from the previous timepoint and adding these time weighted PID scores together over the intervals from 0-48 hours. PID is ranging from 0 to 10 point and SPID0-48 ranging from 0 to 480. A higher value of SPID indicated greater pain relief.
| units on a scale*hours | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time-weighted SPID From 0 to 48 Hours After Dosing (SPID 0-48) | 151.50 ± 11.097 | 68.31 ± 11.195 |
TCPR is defined as the time (in minutes) to perceptible pain relief as indicated on the first stopwatch, provided that the participant also stopped the second stopwatch indicating meaningful pain relief.
| Minutes | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time to Confirmed Perceptible Pain Relief (TCPR) | NA (15 to 720) | NA (0 to 720) |
TMPR is defined as the time (in minutes) to meaningful pain relief as indicated on the second stopwatch.
| Minutes | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time to Meaningful Pain Relief (TMPR) | NA (43.6 to 720) | NA (3.0 to 720) |
Time to first use of rescue medication was measured as the elapsed time from when investigational product was given until the time rescue medication was first given.
| Minutes | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Time to First Use of Rescue Medication | 177.5 (105.0 to 252.0) | 98.0 (79.0 to 118.0) |
Proportion of participants who use rescue medication during the first 12 hours was reported.
| Percent of participants | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| Proportion of Participants Who Use Rescue Medication During the First 12 Hours | 80.6 (71.0 to 89.0) | 93.0 (85.8 to 97.7) |
Collected over Adverse events were collected starting from the time a subject signed and dated the informed consent and until the completion of the subject's last study-related procedure, including contact for follow-up of safety, up to Day 10.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Acetaminophen/Naproxen Sodium Fixed Combination | 0/72 (0%) | 0/72 (0%) | 12/72 (16.7%) |
| Placebo | 0/71 (0%) | 0/71 (0%) | 23/71 (32.4%) |
| Event | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 3/72 | 9/71 |
| NauseaGastrointestinal disorders | 3/72 | 5/71 |
| ConstipationGastrointestinal disorders | 4/72 | 3/71 |
| VomitingGastrointestinal disorders | 1/72 | 3/71 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/72 | 2/71 |
| DizzinessNervous system disorders | 0/72 | 2/71 |
| DiarrhoeaGastrointestinal disorders | 0/72 | 1/71 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/72 | 1/71 |
| Sinus congestionRespiratory, thoracic and mediastinal disorders | 0/72 | 1/71 |
| RashSkin and subcutaneous tissue disorders | 1/72 | 1/71 |
| Age, Continuous(years) | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo | Total |
|---|---|---|---|
| Mean | 44.9 ± 11.90 | 43.6 ± 11.53 | 44.3 ± 11.69 |
| Age, Customized(Participants) | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo | Total |
|---|---|---|---|
| <18 years | 0 | 0 | 0 |
| 18-30 years | 12 | 10 | 22 |
| 31-40 years | 15 | 17 | 32 |
| 41-50 years | 16 | 20 | 36 |
| 51-65 years | 29 | 24 | 53 |
| >65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo | Total |
|---|---|---|---|
| Female | 60 | 58 | 118 |
| Male | 12 | 13 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 27 | 28 | 55 |
| Not Hispanic or Latino | 45 | 43 | 88 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Acetaminophen/Naproxen Sodium Fixed Combination | Placebo | Total |
|---|---|---|---|
| American Indian or Alaska Native | 1 | 1 | 2 |
| Asian | 4 | 4 | 8 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 22 | 20 | 42 |
| White | 41 | 44 | 85 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 4 | 2 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Johnson \& Johnson Consumer Inc. has an agreement with the Yale Open Data Access (YODA) Project to serve as the independent review panel for evaluation of requests for clinical study reports and participant level data from investigators and physicians for scientific research that will advance medical knowledge and public health. Requests for access to the study data can be submitted through the YODA Project site at http://yoda.yale.edu.
Data sharing details ↗ · yoda.yale.edu
Ran from Sep 2023 to primary completion in May 2024, 8 months.
Results were first posted in Nov 2026, 2 years 5 months after primary completion. A results delay was requested in May 2025.
Of 105 industry-sponsored phase 3 interventional studies under Pain, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 23. This study's 8 months is below that.
Counting every sponsor, half of 216 studies reached it within 18 months; a quarter within 9 and three quarters within 38.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Johnson & Johnson Consumer Inc. (J&JCI) →